Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Therapy vs Conversion Therapy for Advanced HCC After Failure of First-line Bevacizumab Plus Sintilimab
NCT07501351Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, regorafenib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Jan 2026; status: recruiting.
02
Drugs
lenvatinibregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07501351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501351.